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Abstract: Background: Liver transplantation for inherited metabolic
disorders aims to save the patient’s life when the disorder is expected to
progress to organ failure, and to cure the underlying metabolic defect.
Methods: We retrospectively analyzed 146 pediatric liver transplants (28
metabolic; 118 non-metabolic) performed between 1986 and 2000.Results:
Twenty-eight transplants were performed in 24 children with metabolic
disease (8 females; 16 males; age range 3 months to 17 yr). Indications
includeda–1-antitrypsin deficiency (n58), two cases each of hyperoxaluria
type 1, Wilson’s disease, hereditary tyrosinemia type I, citrullinemia,
methylmalonicacidemia,andonecaseeachofpropionicacidemia,Crigler–
Najjar syndrome type I, neonatal hemachromatosis, hemophilia B,
Niemann–PickdiseasetypeB,andcysticfibrosis.Eighteentransplantswere
whole organ grafts and 10 were lobar or segmental. Auxiliary liver
transplants were performed in two patients and three received combined
liver-kidney transplants. There were three deaths from sepsis, two from
chronic rejection, and one from fulminant hepatitis. Seven of 10 patients
currently of school age are within 1 yr of expected grade and three who had
pretransplant developmental delay have remained in special education.
Actuarial survival rates at 5 and 10 yr are 78% and 68%, respectively, with
mean follow-up in excess of 5 yr. These results compare favorably to 100
pediatric patients transplantedfornon-metabolicetiologies (65%and61%,
respectively) (p5NS). Conclusions: Pediatric liver transplantation for
metabolic disorders results in excellent clinical and biochemical outcome
with long survival and excellent quality of life for most recipients.
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Introduction
In most pediatric transplant centers, metabolic
liver disease is the second most common indica-
tion for liver transplantation after biliary atresia
(1–4). Liver transplantation in inherited meta-
bolic disorders has a twofold aim: to save the
patient’s life when the disorder is expected to
progress to hepatic (or other organ) failure and to
cure the underlying metabolic defect. Unlike
patients with biliary atresia who develop symp-
toms related to chronic liver disease, many
patients with metabolic liver diseases are trans-
planted to prevent potential complications. The
clinical status of these patients at the time of
transplant is usually better than for other chronic
hepatobiliary diseases, and the survival rate of
patients is higher (3, 4). In this report, we
compare the outcome of pediatric patients
transplanted for metabolic disease to children
transplanted for non-metabolic etiologies.
Additionally, we assessed outcomes in children
Abbreviations: EBV: Epstein–Barr viral syndrome, CNS: Crigler–
Najjar syndrome, B-UGT: bilirubin-UDP-glucuronosyltransferase.
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with metabolic disease stratified by the presence
or absence of underlying parenchymal liver
damage.
Patients and methods
Between 1986 and 2000, 124 pediatric patients at the University of
Michigan Health System received 146 liver transplants. Of these, 28
transplants were performed in 24 children with liver-associated
metabolic disease (8 females; 16 males; mean age 966 yr, range
3 months to 17 yr). Indications included a–1-antitrypsin deficiency
(n58), primary hyperoxaluria type 1 (n52), Wilson’s disease (n52),
hereditary tyrosinemia type I (n52), citrullinemia (n52), methyl-
malonic acidemia (n52), propionic acidemia (n51) Crigler–Najjar
syndrome type I (n51), neonatal hemochromatosis (n51), hemo-
philia B (n51), Niemann–Pick disease type B (n51), and cystic
fibrosis (n51) (Tables 1 and 2). Eighteen transplants were whole
organ grafts and 10 were lobar or segmental grafts. Auxiliary liver
transplants were performed in two patients (Crigler–Najjar;
methylmalonic acidemia) and three received combined liver-
kidney transplants (hyperoxaluria [n52]; methylmalonic acidemia
[n51]). Retransplants were performed in four cases (two each of
chronic rejection and hepatic artery thrombosis). Initial immuno-
suppression was based on cyclosporin A (n520) or tacrolimus
(n54), in combination with steroids and azathioprine (n517),
mycophenolate mofetil (n54), basiliximab (Simulect, Novartis,
Basel, Switzerland) (n51) or anti-CD3 monoclonal antibody
(Orthoclone-OKT3; Ortho Pharmaceuticals, Raritan, NJ) (n51).
Analysis of patient survival was performed by Kaplan–Meier
life-table analysis. Statistical analyses were performed using
STATVIEW version 4.5 (Abacus Concepts Inc., Berkeley, CA).
Statistical significance was accepted at p ,0.05.
Results
In the group with metabolic disease, actuarial
patient survival rates at 5 and 10 yr were 78% and
68%, respectively, with mean follow-up greater
than 5 yr. These results compared favorably to
100 pediatric patients transplanted for non-
metabolic etiologies (65% and 61%, respectively;
p 5 NS vs. metabolic group) (Fig. 1). A subset
analysis of patients with metabolic disease and
cirrhosis (Table 1) and those with metabolic
disease and normal liver function (Table 2),
demonstrated comparable actuarial survival
rates at 5 yr (79% and 75%, respectively).
Among the 24 children in the metabolic group,
12 were treated for graft rejections by steroid
bolus alone (n54) or in combination with OKT3
(n58). Three patients developed Epstein–Barr
viral syndrome (EBV) and potential post-trans-
plant lymphoproliferative disease. The etiology of
metabolic disease in these patients was tyrosine-
mia, methylmalonic acidemia and Crigler–Najjar.
Only one patient had been treated for rejection
with steroid pulses and OKT3 prior to the onset
of elevated EBV titers; all were successfully
treated with a reduction of immunosuppression
and intravenous ganciclovir. There were three
deaths from sepsis, two from chronic rejection,
and one due to fulminant hepatitis (Tables 1 and
2). Seven of 10 patients currently of school age
are within 1 yr of expected grade and three who
had pretransplant developmental delay have
remained in special education.
Discussion
For the majority of children with metabolic
disease, the decision to offer liver transplantation
is made easily, since the extent of liver damage
usually provides a conventional indication.
Additional benefits of liver transplantation











1 a-1-antitrypsin deficiency M neonate 9 yr Whole liver
(Left lobe; Left lobe)
54 Y
2 a-1-antitrypsin deficiency F neonate 4 yr Segments II, III, IV 73 N
3 a-1-antitrypsin deficiency M neonate 4 yr Segments II, III, IV 86 N
4 a-1-antitrypsin deficiency F 6 yr 13 yr Whole liver 91 N
5 a-1-antitrypsin deficiency M neonate 4 yr Whole liver 66 N
6 a-1-antitrypsin deficiency M 12 yr 13 yr Whole liver 24 Y
7 a-1-antitrypsin deficiency M 15 yr 17 yr Whole liver 51 N
8 a-1-antitrypsin deficiency F 4 months 9 yr Whole liver 19 N
9 Wilson’s Disease F 17 yr 17 yr Whole liver 18 N
10 Wilson’s Disease F neonate 17 yr Whole liver 24 N
11 Tyrosinemia F neonate 13 yr Whole liver 23 N
12 Tyrosinemia M neonate 3 yr Whole liver 18 N
13 Neonatal hemochromatosis M neonate 3 months Segments II, III, IV
(Left lobe)
15 Y
14 Hemophilia B M 21 months 14 yr Whole liver 30 Y
15 Niemann–Pick Type B M 12 yr 12 yr Whole liver 113 N
16 Cystic fibrosis M 12 months 4 yr Whole liver 16 N
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depend on the type of genetic defect, whether the
enzymatic defect is located exclusively in the liver
or diffusely throughout all tissues, and the extent
and recoverability of extra-hepatic end-organ
damage.
For example, in both a-1-antitrypsin deficiency
and Wilson’s disease, the liver is the main source
of enzymatic activity and transplantation pro-
vides complete reversal of the metabolic defect.
Additionally, in Wilson’s disease, where copper
overload leads to a progressive accumulation of
copper first in the liver and later in other tissues
(especially the central nervous system), liver
transplantation ameliorates neurological mani-
festations in most patients (5). Similarly, liver
transplantation provides a metabolic cure in
hemophilia A and B by providing the missing
coagulation protein. However, due to the risks of
operation and immunosuppression, liver trans-
plantation should only be performed if hemophi-
lia is complicated by cirrhosis from transfusion-
associated hepatitis (6). In hereditary tyrosinemia
type I, liver and other organ damage occur due to
a widespread enzymatic defect leading to ineffec-
tive tyrosine metabolism. Toxic metabolic by-
products accumulate and cause severe liver injury
ranging from fulminant hepatitis to cirrhosis and
hepatocellular carcinoma (7). The kidney and
central nervous system are also affected. Liver
transplantation treats the liver failure, precludes
the development of hepatocellular carcinoma,
prevents the recurrence of neurological crises,
and may ameliorate renal impairment (8–10). In
neonatal hemochromatosis, patients present with
fulminant hepatic failure in infancy that usually
progresses to death. Liver transplantation offers
the opportunity to replace a metabolically
defective organ and avoid otherwise fatal out-
comes. However, since the etiology of this
disorder may be multifactorial (11), surgical
cure may only be partial.
In a separate group of patients with metabolic
disease, the liver remains structurally normal
while metabolic disease damages other tissues.
The determination as to whether liver transplan-
tation is indicated is more complex, and is
dependent on the extent of organ involvement
outside the liver and whether liver replacement
alone will be sufficient to either prevent further
deterioration or improve dysfunction in extra-
hepatic organs. Illustrative diseases include
primary hyperoxaluria type I, urea cycle dis-
orders, Crigler–Najjar syndrome, and disorders
of organic acid metabolism.
Primary hyperoxaluria type I is characterized
by the continuous excessive synthesis and excre-
tion of oxalic acid, based on a deficiency of
alanine glyoxylate aminotransferase. When the
disease is pyridoxine-resistant, oxalosis results in
progressive nephrocalcinosis, renal failure, and
extrarenal oxalate deposits. The removal of the
enzyme-deficient liver and its replacement with a
normal one cures the liver-associated genetic
defect and prevents the development of renal













17 Primary hyperoxaluria M 5 months 1 yr Whole liver
Kidney transplant
66 N
18 Primary hyperoxaluria M 7 yr 8 yr Segments II, III, IV
Kidney transplant
7 Y
19 Citrullinemia F neonatal 11 yr Segments II, III, IV 60 N
20 Citrullinemia M prenatal 11 yr Whole liver 52 N
21 Methylmalonic acidemia M neonatal 16 yr Whole liver 13 N
(Methylmalonic CoA
mutase deficiency)
22 Methylmalonic acidemia F neonatal 13 yr Heterotopic whole liver 47 N
(mutase O deficiency) Kidney transplant
(Heterotopic whole liver)
23 Propionic Acidemia M neonatal 3 yr Segments II, III 3 Y
24 Crigler–Najjar Type I M 7 months 10 months Auxiliary segments II, III 78 N
Fig. 1. Actuarial patient survival after liver transplantation.
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disease if performed early enough in the patient’s
course (3, 12, 13). Unfortunately, many patients
develop end-stage renal disease by the time the
diagnosis is made. Combined liver and kidney
transplantation is necessary in these patients.
Isolated kidney transplantation fails to cure the
metabolic defect and is usually associated with
recurrent oxalate deposition, which often leads to
graft failure (14). Auxiliary liver transplantation
is not recommended, since the enzymatic defect in
the native liver is associated with ongoing excess
oxalate production (15).
In urea cycle disorders, the biosynthesis of urea
is dependent on six enzymes, all of which are
localized in the liver. Patients usually present in
infancy with severe and often fatal hyperammo-
nemia (16). Most of those who survive have
ongoing cerebral insults with repeated episodes of
hyperammonemia, despite intense medical inter-
vention (17). Liver transplantation cures the
metabolic defect and prevents irreversible neuro-
logic damage if performed early enough (18, 19).
Auxiliary liver transplantation has been advo-
cated by some as a means of preserving the
potential for future gene therapy in the native
liver and also to preserve the native liver as a
reserve in the event of graft failure (18, 19). In our
series, two patients were transplanted for citrulli-
nemia. The first child was born with an antenatal
diagnosis of citrullinemia by amniocentesis. He
initially did well on dietary therapy (protein
restriction). However, he subsequently developed
frequent episodes of hyperammonemia with
progressive behavioral problems and delays in
neurological development. Whole organ liver
transplant was done at 11 yr of age. At 5 yr
follow-up, he has a functioning graft, persistent
behavioral problems and is one grade below
expected for age. He no longer has hyperammo-
nemia and protein intake has been increased. The
second patient presented with hyperammonemic
coma after birth. Despite a severely restricted
protein diet, she endured many decompensations
and suffered from psychomotor retardation. At
11 yr of age she received a cadaveric left lobe
transplant, and had an uncomplicated post-
operative course. At 5 yr follow-up, she is
doing well but remains in special education
classes.
Crigler–Najjar syndrome (CNS) is due to a
complete (type I) or incomplete (type II) defi-
ciency of the hepatocyte enzyme bilirubin-UDP-
glucuronosyltransferase (B-UGT) resulting in
unconjugated hyperbilirubinemia (20). CNS
type II is distinguished by partial B-UGT activity,
which can be induced by phenobarbital to lower
bilirubin levels usually at least by 25% (21).
Kernicterus is a serious complication of both
CNS types I and II (20). It can precipitate without
warning and if full-blown is irreversible.
Treatment of CNS type I consists of exchange
transfusions soon after birth followed by photo-
therapy until liver transplantation can be done
(22, 23). Treatment of CNS type II consists of
phenobarbital and the avoidance of drugs that
displace bilirubin from its binding to albumin.
Children with both types of CNS are usually both
physically and mentally entirely healthy, until
they suddenly develop kernicterus. For this
reason, the decision to transplant an affected
child who is jaundiced but otherwise healthy is
often postponed, sometimes until it is too late.
Auxiliary liver transplantation has been recom-
mended to spare the native liver for possible
future gene therapy or hepatocyte transplanta-
tion (24, 25). Our patient with Crigler–Najjar
syndrome type I received an auxiliary left lateral
segment graft at 10 months of age prior to the
onset of neurologic deficiencies. He is currently
within 1 yr of expected grade at school with good
liver function and no hyperbilirubinemia.
Methylmalonic acidemia and propionic acid-
emia are disorders of organic acid metabolism
caused by a defect in methylmalonyl-CoA mutase
or its cofactor and propionic carboxylase,
respectively. Despite intense medical efforts,
accumulation of toxic metabolites usually results
in death. The few who survive suffer decom-
pensations and numerous complications, parti-
cularly severe cerebral insults (26). Patients with
methylmalonic acidemia, in addition, may also
develop chronic renal failure (26–28). After liver
transplantation, the clinical phenotype is cor-
rected and metabolic decompensations usually do
not recur (27, 29). However, since the metabolic
error has only been corrected in liver tissue and
the liver is not able to clear all extra-hepatic
breakdown products of precursor catabolism,
patients usually have persistent excretion of
urinary metabolites and mild metabolic acidosis.
In our series, three patients were transplanted for
disorders of branched-chain amino acid metabo-
lism, two with methylmalonic acidemia and one
with propionic acidemia. The latter patient did
not survive the perioperative period. The two
patients with methylmalonic acidemia presented
in the newborn period with lethargy, metabolic
acidosis and hyperammonemia. Initially, with
conventional therapy, they fared well. One
patient, who had methylmalonic acidemia due
to mutase O deficiency, made appropriate devel-
opmental and neurological progress, but because
Kayler et al.
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of early episodes of severe metabolic acidosis,
underwent whole liver transplantation at
16 months of age. After 13 months of follow-
up he is well with a good quality of life. The other
patient had methylmalonic acidemia due to
congenital absence of methylmalonic CoA
mutase. She developed many late complications
of the disease including anemia, pancreatitis,
gastrostomy tube dependence, chorea and devel-
opmental delay necessitating special education
classes. By the age of 8 yr, she was hypertensive
with renal failure and had become wheelchair
bound. She received a combined heterotopic
whole liver and kidney transplant at 13 yr of
age. The post-operative course was complicated
by hepatic artery thrombosis necessitating
another heterotopic whole liver transplant,
which was successful. She made a gradual
recovery and at 4 yr follow-up, her appetite is
improved, she is mildly developmentally delayed
and she is ambulatory. This case illustrates the
benefit of heterotopic transplantation in the event
of graft failure.
Short and long-term survival has been
excellent in this current series of patients with
metabolic disease, with no operative mortality
and 5- and 10-yr survival rates of 78% and
65%. These results are comparable to the 75%
to 80% survival rates reported at 5 yr by other
centers (2, 30). Currently, all of our school-age
survivors are able to attend school. The old
paradigm of only transplanting patients with
end-stage-liver disease has given way to intri-
guing circumstances in which transplantation
serves to prevent or ameliorate other end-organ
damage. Among patients whose metabolic
disease threatens the central nervous system,
quality of life is particularly improved if
transplantation is performed prior to the
onset of permanent neurological deficits.
Living donors may be especially helpful in
this subgroup by providing for timely trans-
plantation. Heterotopic or auxiliary liver trans-
plantation should be considered in some
patients with hepatic-based enzyme deficiencies
and normal structural liver function to spare
the native liver for possible future gene therapy
and to provide a hepatic reserve in the event of
graft failure.
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